Warsaw
, Poland Short communication
Lipoprotein Apheresis – Own Experience
Author(s):
Marta Hreńczuk*, Tomasz Piątek and Piotr Małkowski
Low density lipoprotein (LDL) apheresis is utilized in clinical practice with patients suffering from lipid disorders with a high and very high cardiovascular risk. One treatment allows to reduce the concentration of LDL by 55 – 80%. These treatments are recommended primarily for patients with a familial homozygous hypercholesterolemia, for whom treatments should be commenced as early as at the age of 5-8 years old. Therapy is also used for patients with a heterozygous form of hypercholesterolemia if, despite maximum doses of statins, further progress of clinically symptomatic atherosclerosis is observed. Apheresis is recommended when, despite a diet and maximum tolerable pharmacotherapy, the concentration of LDL is ≥ 300 mg/dl (7,7 mmol/l) or ≥ 200 mg/dl (5,2 mmol/l) throughout 6 months for patients with documented coronary heart disease. In r.. Read More»
Annals of Medical and Health Sciences Research received 15898 citations as per google scholar report